Fundz

Lisata Therapeutics

Basking Ridge, New Jersey, United States · Biotechnology, Health Care, Pharmaceutical

Lisata Therapeutics Inc (NASDAQ:LSTA) is a pharmaceutical company that is partnering with the University of Cincinnati to investigate endometriosis therapy.

Key facts

Headquarters
Basking Ridge, New Jersey, United States
Employees
42
Industries
Biotechnology, Health Care, Pharmaceutical
Status
Public (LSTA)
Website
www.lisata.com
LinkedIn
Company page

Recent activity at Lisata Therapeutics

  • : Lisata Therapeutics Acquires Marea Therapeutics in Strategic Merger
  • : Lisata Therapeutics raises $225 million in a concurrent private placement as part of its acquisition of Marea Therapeutics. The funds will help advance clinical trials for key product candidates.
  • : SEC 8-K (8.01): On November 19, 2026, Lisata Therapeutics, Inc. announced a reverse stock split through a press release. This reverse stock split will affect the Common Stock and will become effective shortly, with the adjusted trading beginning soon thereafter. The press release outlines key information regarding the reverse stock split, including strategic implications for shareholders, although specific financial impacts were not detailed in the release. This action is aimed at improving the stock's market visibility and aligning with the company’s long-term financial strategy.
  • : SEC 8-K (5.02): On November 9, 2026, Lisata Therapeutics, Inc. held its annual stockholder meeting where significant corporate governance changes were made. The stockholders approved the 2026 Equity Incentive Plan, which reserves 44,764,472 shares of common stock and includes an annual automatic increase in shares starting January 1, 2027. Additionally, the 2026 Employee Stock Purchase Plan was approved with a reserve of 3,730,372 shares, also set to increase annually until January 1, 2036. These plans will facilitate employee compensation and benefit structures, impacting employee retention and motivation, and reflecting the company's strategy to enhance shareholder value through incentivizing employees.
  • : SEC 8-K (5.02): On October 13, 2026, Lisata Therapeutics, Inc. increased its Board of Directors from seven to eight members, appointing Jeffrey Farrow as a Class III member to fill the newly created position. His term will expire at the Company's 2028 annual meeting of stockholders. Farrow, 65, is the Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. since April 2023, and holds directorships at Clover Biopharmaceuticals and Achieve Life Sciences. His extensive experience spans key financial roles in multiple biopharmaceutical companies, enhancing the Board’s expertise significantly.
  • : SEC 8-K (1.01): On September 17, 2026, Lisata Therapeutics, Inc. completed an acquisition of Marea Therapeutics, Inc. through a Merger Agreement signed on the same day. This transaction involved Lisata, with its subsidiaries Mariner Merger Sub I, Inc. and Mariner Merger Sub II, LLC, where First Merger Sub merged into Marea, resulting in Marea becoming a wholly owned subsidiary of Lisata. The strategic implication of this acquisition is expected to enhance Lisata's therapeutic development pipeline, potentially leading to increased market presence and synergies in research and development efforts.
  • : SEC 8-K (5.02): On August 3, 2026, the Company terminated the employment of Dr. Kristen K. Buck, M.D., the Executive Vice President of R&D and Chief Medical Officer, as part of a Board-approved reduction in workforce. This termination is classified as 'without Cause' under her employment agreement, entitling her to a severance package of 12 months' base salary and bonus compensation, along with COBRA premiums for herself and dependents for up to 12 months. Additionally, on the same date, the Board approved a $200,000 cash retention bonus for James Nisco, the Senior Vice President, Finance and Treasury, contingent upon continued employment through December 31, 2026, and terms related to potential termination without Cause. This series of management changes was strategic in response to organizational restructuring.
  • : SEC 8-K (1.02): On July 24, 2026, Lisata Therapeutics, Inc. terminated the Merger Agreement with Kuva Labs Inc. and Kuva Acquisition Corp. due to the latter's failure to finance the tender offer for their common shares, which had expired on July 20, 2026. The termination triggers a $2,000,000 fee payable to Lisata by Parent, alongside potential legal remedies for breach. The merger aimed to acquire all outstanding shares at $4.00 each plus contingent value rights potentially worth up to $3.00 per share, depending on milestone achievements. This event significantly impacts Lisata's strategic positioning and cash flow, as they seek damages for breaches that occurred amid financing troubles for the acquirer.
  • : SEC 8-K (1.01): On July 16, 2026, Lisata Therapeutics, Inc. entered into an amendment to the previously announced Agreement and Plan of Merger with Kuva Labs Inc. and its wholly owned subsidiary, Kuva Acquisition Corp. The Amendment extends the Outside Date of the Merger Agreement from July 17, 2026, to July 21, 2026. This extension is significant as it allows additional time for the completion of the merger process. Key parties involved include Lisata Therapeutics, Kuva Labs Inc., and Kuva Acquisition Corp.
  • : SEC 8-K (1.01): On June 8, 2026, Lisata Therapeutics, Inc. entered into an amendment to a previously announced Merger Agreement with Kuva Labs Inc. and its wholly owned subsidiary, Kuva Acquisition Corp. The Amendment extends the deadline for the tender offer for Lisata's common stock from June 1, 2026, to June 10, 2026, and the Outside Date from July 1, 2026, to July 17, 2026. Notably, it allows Parent to pay a non-refundable extension fee of $1,500,000 to further extend this date to August 17, 2026. Additionally, the Company has agreed not to pursue claims against Parent arising from the Merger Agreement until that date, and it involves specific payment terms including $150,000 due on June 12, 2026, and $100,000 due on June 26, 2026. Significant implications for this Amendment may impact the timeline and conditions under which the merger is completed.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Lisata Therapeutics funding history

DateRoundAmount
Sep 2026Series C$351.9M
Feb 2021Venture$25.0M
Jul 2020Seed$2.0M
Jun 2020Seed$2.2M
May 2020Seed$2.4M

Leadership

  • David, President and Chief Executive Officer, Member of the Board of Directors at Lisata Therapeutics
  • David Mazzo, Executive Officer, Director
  • Michael Davidson, Director
  • Anne Whitaker, Director
  • Steven Klosk, Director
  • Gregory Brown, Director
  • Steven Myers, Director
  • Cynthia Schwalm, Director
  • Peter Traber, Director

Verified email and direct lines for Lisata Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Lisata Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Lisata Therapeutics in the news

Companies similar to Lisata Therapeutics

About Lisata Therapeutics: questions and answers

What does Lisata Therapeutics do?

Lisata Therapeutics Inc (NASDAQ:LSTA) is a pharmaceutical company that is partnering with the University of Cincinnati to investigate endometriosis therapy.

Where is Lisata Therapeutics headquartered?

Lisata Therapeutics is headquartered in Basking Ridge, New Jersey, United States.

How many employees does Lisata Therapeutics have?

Lisata Therapeutics has about 42 employees.

Has Lisata Therapeutics raised funding?

Yes. Fundz has recorded 5 funding events for Lisata Therapeutics. The most recent, Series C of $351.9M, was in Sep 2026.

Who leads Lisata Therapeutics?

David is a President and Chief Executive Officer, Member of the Board of Directors at Lisata Therapeutics at Lisata Therapeutics.

What is the latest news on Lisata Therapeutics?

On Sep 17, 2026, Lisata Therapeutics Acquires Marea Therapeutics in Strategic Merger

Is Lisata Therapeutics a public company?

Yes. Lisata Therapeutics is publicly traded under the ticker LSTA.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Lisata Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.